Treating obsessive-compulsive disorder in patients with Bipolar disorder

Comparison Aripiprazole & Risperidone effectiveness in treating obsessive-compulsive disorder in patients with Bipolar disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200614047761N1

Enrollment

Registered

2020-06-18

Start date

2020-04-09

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Bipolar disorder. Condition 2: Obsessive-Compulsive disorder. Bipolar disorder Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Aripiprazole (Sobhan Company) Begins with an initial dose of 2.5 mg per day and gradually increased to a dose of 5 to 20 mg per day. Intervention 2: Intervention gr

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with bipolar mood disorder Have not Major medical problem (cardiovascular, respiratory, renal and gastrointestinal disease)

Exclusion criteria

Exclusion criteria: Pregnancy alcohol or other substances abuser

Design outcomes

Primary

Measure	Time frame
Obsessive-compulsive signs&symptoms in bipolar disorder patients. Timepoint: before intervention and then monthly for 4 months. Method of measurement: Yale- Brown Obsessive Compulsive Scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSekineh Javadian

Babol University of Medical Sciences

s.javadian@mubabol.ac.ir+98 11 3219 2033

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026